Novartis has reported that findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna (nilotinib) to  Gleevec (imatinib mesylate) tablets at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient populations, including newly diagnosed patients, patients with residual disease who switched to Tasigna after long-term treatment with Gleevec, and patients who failed to respond to frontline Gle...